InflaRx (IFRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• InflaRx is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.07 per share and revenue of approximately $0.01 million.
• The company previously reported a quarterly loss of $0.11 per share, missing the $0.07 consensus estimate. Analysts project losses of $0.31 per share for the current fiscal year and $0.38 for the next.
• InflaRx shares opened at $1.73, while Wall Street’s average rating is “Moderate Buy” with a consensus price target of $7.43; targets range from $6.00 to $8.00 among bullish analysts.

InflaRx (NASDAQ:IFRX - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.07) per share and revenue of $0.01 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 9:30 AM ET.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, analysts expect InflaRx to post ($0.31) EPS for the current fiscal year and ($0.38) EPS for the next fiscal year.

InflaRx Price Performance

NASDAQ IFRX opened at $1.73 on Thursday. The stock's fifty day moving average price is $1.88 and its 200 day moving average price is $1.62. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The company has a market cap of $254.95 million, a price-to-earnings ratio of -2.98 and a beta of 2.59.

Wall Street Analyst Weigh In

IFRX has been the topic of several research analyst reports. Cantor Fitzgerald boosted their price target on InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Zacks Research lowered InflaRx from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 25th. Needham & Company LLC began coverage on shares of InflaRx in a report on Monday, September 14th. They issued a "buy" rating and a $8.00 price target on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.43.

InflaRx Company Profile

InflaRx N.V. NASDAQ: IFRX is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company's research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company's lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.